The process development challenge for a new vaccine

Nature Medicine

Volumn 11, Issue 4S, 2005, Pages S16-

  Buckland, Barry C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; VACCINE; VARICELLA ZOSTER VACCINE;

DRUG INDUSTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RISK BENEFIT ANALYSIS; ROTAVIRUS; SACCHAROMYCES CEREVISIAE; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS; VERO CELL; VIRUS PARTICLE; WART VIRUS;

HERPES ZOSTER; HERPESVIRUS VACCINES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TECHNOLOGY, PHARMACEUTICAL; VACCINES;

HUMAN HERPESVIRUS 3; HUMAN PAPILLOMAVIRUS TYPES; ROTAVIRUS; SACCHAROMYCES CEREVISIAE;

EID: 17644424942     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1218     Document Type: Article

References (8)

1. Jansen, K.U. et al. Vaccine 13, 1509-1514 (1995).
2. Knicksen, P.J. & Miller, W.J. in Vaccines: New Approaches to Immunological Problems (ed. Ellis, R.W.) 177-204 (Butterworth-Heinemann, Stoneham, Massachusetts, 1992).
3. Brown D.R. et al. Vaccine 22, 2936-2942 (2002).
4. Fife, K.H. et al. Vaccine 22, 2943-2952 (2002).
5. Koutsky, L.A. et al. N. Engl. J. Med. 347, 1645-1651 (2002).
6. Clark, H.F. et al. Pediatr. Infect. Dis. J. 22, 14-20 (2003).
7. Clark, H.F. et al. J. Pediatr. 144, 184-190 (2004).
8. Pisano, G.P. in The Development Factory (Harvard Business School Press, Boston, 1997).